

## **Singapore**

25 July 2025


# Singapore's June manufacturing output accelerated to 8.0% YoY (0.0% MoM sa).


#### Selena Ling Head of Research and Strategy lingssselena@ocbc.com

### **Highlights:**

- Singapore's strong manufacturing performance sustained into June, expanding by 8.0% YoY which is an improvement from the 3.6% YoY registered in May. This is also the best YoY growth since November 2024, although in month-on-month sequential terms it was flat compared to May. Excluding biomedical manufacturing, output rose 8.2% YoY (-0.8% MoM sa). This beat Bloomberg market consensus forecast of 7.1% YoY (-1.6% MoM sa) and our forecast for 5.6% YoY (-2.8% MoM sa).
- Frontloading and resilient eternal demand continued to provide a tailwind. The acceleration in growth momentum was led by precision engineering which saw the second consecutive month of double-digit growth at 18.9% YoY, largely attributable to machinery & systems (19.3% YoY) due to demand for semiconductor equipment and process control equipment, as well as precision modules & components (17.9% YoY amid higher plastic and metal precision component, optical instrument and electronics connector industries. Separately, the biomedical manufacturing industry also did well at 11.3% YoY, driven by the pharmaceuticals (3.8% YoY due to low base effects) whilst the medical technology segment declined 2.5% YoY. The transport engineering industry also saw output growth of 9.2% YoY (May: 25.6% YoY), aided by the aerospace segment (20.6%) amid strong maintenance, repair and overhaul (MRO) activity pipeline from commercial airlines, whereas the marine & offshore engineering and land segments were lacklustre. Electronics output also grew 6.6% YoY, bolstered by strong production of infocomms & consumer electronics \*22.4% YoY) and semiconductors (4.3%), albeit the computer peripherals & data storage and other electronic modules & components fared poorly.
- For the first half of 2025, manufacturing output increased 8.2% YoY, setting a strong start which could be partly attributable to frontloading ahead of anticipated US tariffs as well as stronger-than-expected external demand in key markets. Given the imminent US reciprocal tariff implementation on 1 August, as well as the potential sectoral tariffs on semiconductors and pharmaceuticals, there could be some risk of a payback moderation into 2H25. As highlighted by MTI during the advance 2Q25 GDP growth estimates, there remain significant uncertainty and downside risks in the global economy in the second half of 2025 given the lack of clarity over the tariff policies of the US. Singapore has not received a letter regarding its reciprocal tariff rate, so the assumption is that it is unlikely to deviate from the initial 10% level announced on Liberation Day. The bigger question is it there will be any concessions given for the sectoral tariffs that could be

impending for semiconductors and pharmaceuticals that could mean a bigger hit to domestic manufacturing growth looking ahead.





Source: EDB.



#### Macro Research

Selena Ling

Head of Research & Strategy lingssselena@ocbc.com

Herbert Wong

Hong Kong & Taiwan Economist herberthtwong@ocbc.com

Jonathan Ng

ASEAN Economist jonathanng4@ocbc.com

## FX/Rates Strategy

Frances Cheung, CFA Head of FX & Rates Strategy

francescheung@ocbc.com

#### Credit Research

Andrew Wong Head of Credit Research wongvkam@ocbc.com

Chin Meng Tee, CFA Credit Research Analyst mengteechin@ocbc.com Tommy Xie Dongming

Head of Asia Macro Research xied@ocbc.com

Lavanya Venkateswaran Senior ASEAN Economist

lavanyavenkateswaran@ocbc.com

Ong Shu Yi

ESG Analyst

shuyiong1@ocbc.com

Christopher Wong

FX Strategist

christopherwong@ocbc.com

Ezien Hoo, CFA

Credit Research Analyst ezienhoo@ocbc.com Keung Ching (Cindy)

Hong Kong & Macau Economist cindvckeuna@ocbc.com

Ahmad A Enver

ASEAN Economist

ahmad.enver@ocbc.com

Wong Hong Wei, CFA Credit Research Analyst wonghongwei@ocbc.com

This report is solely for information purposes and general circulation only and may not be published, circulated, reproduced or distributed in whole or in part to any other person without our prior written consent. This report should not be construed as an offer or solicitation for the subscription, purchase or sale of the securities/instruments mentioned herein or to participate in any particular trading or investment strategy. Any forecast on the economy, stock market, bond market and economic trends of the markets provided is not necessarily indicative of the future or likely performance of the securities/instruments. Whilst the information contained herein has been compiled from sources believed to be reliable and we have taken all reasonable care to ensure that the information contained in this report is not untrue or misleading at the time of publication, we cannot guarantee and we make no representation as to its accuracy or completeness, and you should not act on it without first independently verifying its contents. The securities/instruments mentioned in this report may not be suitable for investment by all investors. Any opinion or estimate contained in this report is subject to change without notice. We have not given any consideration to and we have not made any investigation of the investment objectives, financial situation or particular needs of the recipient or any class of persons, and accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of the recipient or any class of persons acting on such information or opinion or estimate. This report may cover a wide range of topics and is not intended to be a comprehensive study or to provide any recommendation or advice on personal investing or financial planning. Accordingly, it should not be relied on or treated as a substitute for specific advice concerning individual situations. Please seek advice from a financial adviser regarding the suitability of any investment product taking into account your specific investment objectives, financial situation or particular needs before you make a commitment to purchase the investment product. In the event that you choose not to seek advice from a financial adviser, you should consider whether the investment product mentioned herein is suitable for you. Oversea-Chinese Banking Corporation Limited ("OCBC Bank"), Bank of Singapore Limited ("BOS"), OCBC Investment Research Private Limited ("OIR"), OCBC Securities Private Limited ("OSPL") and their respective related companies, their respective directors and/or employees (collectively "Related Persons") may or might have in the future, interests in the investment products or the issuers mentioned herein. Such interests include effecting transactions in such investment products, and providing broking, investment banking and other financial or securities related services to such issuers as well as other parties generally. OCBC Bank and its Related Persons may also be related to, and receive fees from, providers of such investment products. There may be conflicts of interest between OCBC Bank, BOS, OIR, OSPL or other members of the OCBC Group and any of the persons or entities mentioned in this report of which OCBC Bank and its analyst(s) are not aware due to OCBC Bank's Chinese Wall arrangement. This report is intended for your sole use and information. By accepting this report, you agree that you shall not share, communicate, distribute, deliver a copy of or otherwise disclose in any way all or any part of this report or any information contained herein (such report, part thereof and information, "Relevant Materials") to any person or entity (including, without limitation, any overseas office, affiliate, parent entity, subsidiary entity or related entity) (any such person or entity, a "Relevant Entity") in breach of any law, rule, regulation, guidance or similar. In particular, you agree not to share, communicate, distribute, deliver or otherwise disclose any Relevant Materials to any Relevant Entity that is subject to the Markets in Financial Instruments Directive (2014/65/EU) ("MiFID") and the EU's Markets in Financial Instruments Regulation (600/2014) ("MiFIR") (together referred to as "MiFID II"), or any part thereof, as implemented in any jurisdiction. No member of the OCBC Group shall be liable or responsible for the compliance by you or any Relevant Entity with any law, rule, regulation, guidance or similar (including, without limitation, MiFID II, as implemented in any jurisdiction)

The information provided herein may contain projections or other forward looking statements regarding future events or future performance of countries, assets, markets or companies. Actual events or results may differ materially. Past performance figures are not necessarily indicative of future or likely performance.

Privileged / confidential information may be contained in this report. If you are not the addressee indicated in the message enclosing the report (or responsible for delivery of the message to such person), you may not copy or deliver the message and/or report to anyone. Opinions, conclusions and other information in this document that do not relate to the official business of OCBC Bank, BOS, OIR, OSPL and their respective connected and associated corporations shall be understood as neither given nor endorsed.



Co.Reg.no.: 193200032W